ALK-Abelló
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
ALK | CO
Overview
Corporate Details
- ISIN(s):
- DK0061802139
- LEI:
- 529900SGCREUZCZ7P020
- Country:
- Denmark
- Address:
- Bøge Alle 6-8, 2970 Hørsholm
- Website:
- https://www.alk.net
- Sector:
- Manufacturing
Description
ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2017-05-04 21:07 |
ALKs tabletvaccine mod hustøvmideallergi, ACARIZAX®, godkendt i Canada
|
English | TXT • 2.1 KB | ||
| 2017-05-04 21:07 |
ALKs tabletvaccine mod hustøvmideallergi, ACARIZAX®, godkendt i Canada
|
English | PDF • 22.4 KB | ||
| 2017-04-16 20:03 | Danish | TXT • 3.1 KB | |||
| 2017-04-16 20:03 | English | PDF • 23.4 KB | |||
| 2017-04-16 20:02 | Danish | TXT • 3.1 KB | |||
| 2017-04-16 20:02 | English | TXT • 3.0 KB | |||
| 2017-04-16 20:00 |
ACARIZAX® godkendt til brug i unge patienter med husstøvmide-allergi i Europa
|
English | PDF • 23.6 KB | ||
| 2017-04-16 20:00 |
ACARIZAX® godkendt til brug i unge patienter med husstøvmide-allergi i Europa
|
English | TXT • 3.0 KB | ||
| 2017-04-16 20:00 |
ACARIZAX® godkendt til brug i unge patienter med husstøvmide-allergi i Europa
|
English | PDF • 23.4 KB | ||
| 2017-04-16 20:00 |
ACARIZAX® godkendt til brug i unge patienter med husstøvmide-allergi i Europa
|
Danish | TXT • 3.1 KB | ||
| 2017-03-24 08:01 | Danish | TXT • 3.8 KB | |||
| 2017-03-24 08:01 | English | PDF • 33.1 KB | |||
| 2017-03-24 08:00 |
ALKs partner, Torii, indsender registreringsansøgning for tabletvaccinen mod hu…
|
English | TXT • 3.9 KB | ||
| 2017-03-24 08:00 |
ALKs partner, Torii, indsender registreringsansøgning for tabletvaccinen mod hu…
|
English | PDF • 32.6 KB | ||
| 2017-03-23 15:03 | Danish | TXT • 6.2 KB |
Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALK-Abelló
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALK-Abelló via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
